Recent advancements in Artificial Intelligence (AI) have revolutionized the application of electrocardiography (ECG) in cardiovascular diagnostics. The AI-ECG analysis market size is expected to grow from $2.01 billion in 2025 to $2.40 billion in 2026 at a compound annual growth rate (CAGR) of 19.3% (per the Business Research report).
Against this backdrop, Tempus AI TEM is expanding its cardiovascular portfolio with a suite of next-generation AI products designed to identify patients at risk for complex cardiac conditions.
Tempus received 510(k) clearance from the Food and Drug Administration (FDA) for its Tempus ECG-MR, an AI product that analyzes standard 12-lead resting electrocardiograms (ECGs) to detect signs associated with undiagnosed moderate or severe mitral regurgitation (MR).
Additionally, Tempus AI received 510(k) clearance from the FDA for Tempus ECG-PH (pulmonary hypertension), an AI-enabled software device that analyzes standard 12-lead ECGs for signs associated with pulmonary hypertension. Tempus ECG-PH only analyzes ECG data and provides a binary output for interpretation.
Peer Update
GE HealthCare’s GEHC new Advanced Imaging Solutions (AIS) segment combines the former Imaging and AVS businesses, linking CT, MR, molecular imaging, interventional systems, ultrasound, software and services under one operating structure. In second-quarter 2026, AIS generated $3.77 billion in revenues, up 5.0% organically, while segment EBIT margin rose 90 basis points to 13.9%. GEHC expects higher-margin AI-enabled new products in MR and CT, together with deeper clinical and commercial alignment, to support growth as the innovation cycle progresses.
iRhythm Holdings’ IRTC platform is supported by more than 3 billion hours of curated ECG data, more than 12 million patient reports and an expanding clinical evidence base. During the second quarter of 2026, iRhythm expanded work with Desert Oasis Healthcare and signed two commercial agreements through Luum that combine predictive workflows with monitoring. Early pilot programs have shown more than 85% accuracy in identifying patients with clinically relevant arrhythmias before diagnosis. The productivity case also advanced after FDA clearance of iRhythm’s third-generation algorithm.
TEM’s Stock Price Performance
In the past year, Tempus’ shares have declined 17.7% compared with the industry’s 10.4% decline.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 7.30X compared with the industry average of 4.82X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus’ loss per share estimate for 2026 has moved north.
Image Source: Zacks Investment Research
TEM currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Tempus AI, Inc. (TEM): Free Stock Analysis Report
iRhythm Holdings, Inc. (IRTC): Free Stock Analysis Report
GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).